Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 11/20 | 0.58 |
| ▸ | CYBB | P04839 | 5/20 | 0.58 |
| ▸ | NOX5 | Q96PH1 | 4/20 | 0.49 |
| ▸ | NOX1 | Q9Y5S8 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219755 | 0.88 | NOX4 (0.54) | NOX4CYBBNOX5NOX1KCNH2 | |
| SCHEMBL2217360 | 0.83 | NOX4 (0.69) | NOX4CYBBNOX5NOX1KCNH2 | |
| SCHEMBL2217532 | 0.82 | NOX4 (0.50) | NOX4CYBBNOX5NOX1HRH3 | |
| SCHEMBL2216293 | 0.81 | NOX4 (0.54) | NOX4CYBBNOX5NOX1KCNH2 | |
| SCHEMBL14992015 | 0.80 | NOX4 (0.51) | NOX4CYBBNOX5NOX1 | |
| SCHEMBL2215706 | 0.75 | NOX4 (0.64) | NOX4CYBBNOX5NOX1CYP3A4 | |
| SCHEMBL2219561 | 0.74 | NOX4 (0.66) | NOX4CYBBNOX5NOX1CYP3A4 | |
| SCHEMBL3618372 | 0.74 | NOX4 (1.00) | NOX4CYBBNOX5NOX1CYP3A4 | |
| SCHEMBL3617349 | 0.74 | NOX4 (0.77) | NOX4CYBBNOX5NOX1CYP3A4 | |
| SCHEMBL2218143 | 0.73 | NOX4 (0.55) | NOX4CYBBNOX5NOX1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | claimed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | claimed |
| EP-2674160-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2013-12-18 | — | — | EP | claimed |
| EP-2349261-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-08-14 | — | — | EP | claimed |
| US-20130143879-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2013-06-06 | — | — | US | claimed |
| US-8455485-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | claimed |
| EP-2349261-A2 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2011-08-03 | — | — | EP | claimed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | claimed |
| WO-2010035219-A2 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | claimed |
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | disclosed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | disclosed |
| US-9012449-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-04-21 | — | — | US | disclosed |
| US-8455485-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-06-04 | — | — | US | disclosed |
| EP-2349261-A2 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| WO-2010035219-A2 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143879-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885NOX5 4/4885 |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885NOX5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.